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Results For all 379 patients all-cause mortality data were 
available. For seven patients (2%) follow-up data on MACE 
was limited, ranging from 129 to 577 days. All others com-
pleted the 2-year follow-up visit. Incidence of MACE was 
11 (5.8%) in metformin and 6 (3.2%) in placebo treated 
patients [hazard ratio (HR) 1.84, confidence interval (CI) 
0.68–4.97, P = 0.22]. Three patients died in the metformin 
group and one in the placebo treatment group. Individual 
components of MACE were also comparable between 
both groups. New-onset diabetes mellitus was 34 (17.8%) 
in metformin and 32 (17.0%) in placebo treated patients 
(odds ratio 1.15, CI 0.66–1.98, P = 0.84). After multivari-
able adjustment the incidence of MACE was comparable 
between the treatment groups (HR 1.02, CI 0.10–10.78, 
P = 0.99).
Conclusions Four months metformin treatment initiated 
at the time of hospitalization in STEMI patients without 
diabetes did not exert beneficial long-term effects.
Trial registration clinicaltrials.gov Identifier: NCT01217307.
Keywords Acute myocardial infarction · Diabetes · Heart 
failure · Percutaneous coronary intervention · Metformin
Introduction
The prognosis of patients presenting with ST-segment 
elevation myocardial infarction (STEMI) has substantially 
improved over the last decades. However, the development 
of heart failure remains an important cause of morbidity 
and mortality for STEMI patients and new strategies to 
reduce this risk are warranted [1].
The dimethylbiguanide metformin, used as first-line 
treatment in patients with type II diabetes mellitus (DM), 
has been suggested to exhibit cardioprotective effects in 
Abstract 
Objectives Preclinical and clinical studies suggested car-
dioprotective effects of metformin treatment. In the GIPS-
III trial, 4 months of metformin treatment did not improve 
left ventricular ejection fraction in patients presenting with 
ST-elevation myocardial infarction (STEMI). Here, we 
report the 2-year follow-up results.
Methods Between January 2011 and May 2013, 379 
STEMI patients without diabetes undergoing primary per-
cutaneous coronary intervention were randomized to a 
4-month treatment with metformin (500  mg twice daily) 
(N = 191) or placebo (N = 188) in the University Medical 
Center Groningen. Two-year follow-up data was collected 
to determine its effect on predefined secondary endpoints: 
the incidence of major adverse cardiac events (MACE), its 
individual components, all-cause mortality, and new-onset 
diabetes.
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the setting of myocardial infarction (MI) in both preclini-
cal and clinical studies irrespective of its glucose-lowering 
properties [2, 3]. Metformin treatment prior to reperfu-
sion has been shown to reduce infarct size in several ani-
mal experimental studies as well as in observational stud-
ies in patients with DM [4]. Outside of the setting of MI, 
chronic metformin treatment in patients with type II DM 
was also associated with lower N-terminal pro-brain natriu-
retic peptide (NT pro-BNP) levels, further supporting a 
potential beneficial effect on the risk of heart failure [5]. 
Furthermore, a favorable effect on adverse remodeling has 
been observed in non-diabetic mice undergoing permanent 
coronary artery ligation, where metformin treatment dur-
ing reperfusion improved left ventricular ejection fraction 
(LVEF) [2]. To test the hypothesis that metformin protects 
the heart against adverse cardiac remodeling after STEMI 
we designed and executed the glycometabolic intervention 
as adjunct to primary percutaneous coronary intervention 
in ST-segment elevation myocardial infarction (GIPS) III 
trial, a randomized, double blinded clinical trial. We previ-
ously published the primary findings of GIPS-III [6]. Four 
months of metformin treatment in patients without DM pre-
senting with STEMI and undergoing primary percutaneous 
coronary intervention (PCI) had no improvement on LVEF. 
In addition, no significant effect was seen on NT pro-BNP 
levels after 4 months; in both groups the median NT pro-
BNP was 167 ng/L (P = 0.66). Glucose regulation was also 
comparable at 4 months, despite metformin treatment [7].
Here, we report the long-term effects of 4  months of 
metformin treatment in STEMI patients without DM on 
predefined secondary endpoints, including major adverse 
cardiac events (MACE).
Methods
The GIPS-III trial was a prospective, double-blind rand-
omized clinical trial. The included patients were admitted 
via the STEMI protocol to the University Medical Center 
of Groningen. Inclusion criteria were: age of 18  years or 
older, STEMI diagnosis, and successful PCI with at least 
one ≥3 mm stent resulting in a subsequent thrombolysis in 
myocardial infarction (TIMI) flow grade of 2 or 3. Previous 
MI, diagnosis of DM, the need for coronary artery bypass 
grafting (CABG), severe renal impairment, and contra-
indications for cardiac magnetic resonance imaging (CMR) 
were considered exclusion criteria. A detailed description 
of the study design, and the rationale of the GIPS-III trial as 
well as the primary results have been published [6, 8]. The 
trial was registered at clincialtrials.gov (NCT01217307).
The study procedures have been described in detail 
previously [6, 8]. In brief, standard laboratory assess-
ment and physical examination were performed on 
admission followed by coronary angiography and PCI. 
Verbal informed consent was obtained during PCI proce-
dure in the presence of an independent witness. After the 
procedure, patients were transferred to the coronary care 
unit, where they were randomly assigned in a 1:1 ratio to 
a 4-month oral treatment with either metformin hydrochlo-
ride (500  mg twice daily) or a visually matching placebo 
using block randomization of six patients. Time of admin-
istration after successful PCI ranged from 81 to 133  min 
in the metformin group and 78–134  min in the control 
group. Written informed consent was obtained during the 
admission at the coronary care unit from all but one (ran-
domized to placebo). This patient was previously excluded 
from further analysis [6] leaving in total 379 patients in this 
2-year follow-up study. All patients were treated concomi-
tantly according to the European practice guidelines for a 
STEMI [1]. Follow-up visits were performed by investiga-
tors blinded to treatment allocation at one and 2 years after 
randomization. During follow-up, NT pro-BNP levels were 
measured at baseline, and on average 3 h, 12 h, 2 weeks, 
6–8  weeks, 4  months and 1  year after baseline. During 
these visits, physical examination, clinical assessment, and 
12-lead electrocardiography were performed and standard 
laboratory assessment was repeated at 1 year.
The principal secondary clinical outcome parameter of 
the current study was the combined incidence of MACE 
(defined as cardiovascular death, recurrent MI or target 
lesion revascularization) 2 years after randomization. Dur-
ing the time of follow-up, all predefined clinical endpoints 
(including death, reinfarction, recurrent coronary interven-
tion, stroke, hospitalization for heart failure or chest pain, 
implantable cardioverter defibrillator (ICD) implantation, 
and new-onset DM [defined as either receiving antidia-
betic medication or a glycated hemoglobin (HbA1c) level 
of ≥6.5% or a glucose level (≥11.1  mmol/L) compatible 
with this diagnosis] were also assessed and adjudicated by 
an independent, blinded to allocation, adjudication com-
mittee [7, 9]. Additional secondary efficacy measures were 
all-cause mortality, the individual components of MACE, 
new-onset DM, and NT pro-BNP levels.
Differences between means of continuous variables with 
a normal distribution were assessed using the two-tailed 
Student’s t test. Log transformation was used to convert 
not normally distributed data to a normal distribution. Dif-
ferences in effect measurements and their 95% confidence 
intervals between the control group and metformin group 
were presented when indicated. Logistic regression with 
concomitant odds ratio (OR) was used to test the treatment 
effect on the endpoint of new-onset DM, as dates were 
not available. Associations between the treatment groups 
and the predefined clinical endpoints were analyzed using 
the Mantel–Cox or log-rank test and presented with haz-
ard ratios (HR). Kaplan–Meier survival curves were used 
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to present all-cause mortality and MACE incidences. Cox 
proportional hazard regression was performed to adjust for 
covariates. Differences in medication use between the con-
trol and metformin group were evaluated with the Fisher’s 
exact test. Linear mixed-effect models were used to assess 
NT pro-BNP levels over time (with last observation car-
ried forward when missing) between treatment groups. A P 
value of <0.05 was considered to indicate statistical signifi-
cance. Analyses were performed using Stata version 13.0 
(StataCorp).
Results
Baseline characteristics of patients included in the GIPS-
III trial were previously reported and are similar between 
the two treatment groups [6]. In short, 191 patients were 
included in the metformin group and 188 in the placebo 
group. The majority was male, Caucasian, were cur-
rent smokers, and had hypercholesterolemia. A history of 
hypertension was present in 30% of the patients. The most 
common infarct-related artery was the right coronary artery 
with a prevalence of 45 and 68% of patients had single ves-
sel disease. Furthermore, the majority of patients had myo-
cardial blush grade 3 and 91% had TIMI flow 3 post-PCI. 
Median peak creatine kinase MB was 163 (interquartile 
range (IQR) 68; 343) U/L in the metformin group and 159 
(IQR 69–300) U/L in the placebo group. Data on mortality 
was available for the entire follow-up period of all 379 
patients. In 7 (2%) patients, 4 in the placebo group and 3 in 
the metformin group, follow-up data on MACE was limited 
ranging from 129 to 577 days; for all other patients, 2-year 
follow-up visits were completed.
During follow-up, MACE occurred in 17 patients (4.5%) 
(Table  1). Two MACE, both target lesion revasculariza-
tions, occurred at the day of randomization. Four patients 
died during follow-up, 1 patient due to a cardiovascular 
cause. Thirteen patients had a recurrent MI of which six 
patients also underwent a target lesion revascularization. 
MACE occurred in 11 (5.8%) patients treated with met-
formin compared to 6 (3.2%) patients treated with placebo 
(HR 1.84, confidence interval (CI) 0.68–4.97, P  =  0.22, 
Fig. 1).
Three patients died of a non-cardiovascular cause. 
Revascularizations of non-infarct-related artery stenoses 
visualized during initial STEMI were mainly performed in 
a staged manner and included in the endpoint as defined by 
our protocol. Therefore, the incidence of non-target lesion 
revascularizations was substantial (17.4%). Of all non-tar-
get lesion revascularizations, 84.8% (N  =  56) were iden-
tified during PCI of the initial STEMI event. In the other 
ten patients receiving a non-target lesion revascularization, 
the median time was after 386  days (range 11–627  days) 
of follow-up. During follow-up, 66 (17.4%) patients devel-
oped DM. The individual components of MACE and 
other predefined clinical outcome parameters were also 
Table 1  Secondary endpoints after 2-year follow-up
Target lesion revascularization is defined as a percutaneous coronary intervention in the same coronary segment as the culprit lesion of the index 
event. Target vessel revascularization is defined as a percutaneous coronary intervention in the same culprit vessel, but not the same coronary 
segment of the index event
MACE major adverse cardiac events, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarc-
tion, CABG coronary artery bypass graft, ICD implantable cardioverter defibrillator, N.A. not applicable
Secondary endpoint Total (N = 379) Metformin (N = 191) Placebo (N = 188) P value
MACE (%) 17 (4.5) 11 (5.8) 6 (3.2) 0.22
 Cardiovascular death (%) 1 (0.3) 1 (0.5) – N.A.
 Reinfarction (%) 13 (3.4) 8 (4.2) 5 (2.7) 0.41
 Target lesion revascularization (%) 9 (2.4) 5 (2.6) 4 (2.1) 0.74
Death (%) 4 (1.1) 3 (1.6) 1 (0.5) N.A.
Non-cardiovascular death (%) 3 (0.8) 2 (1.1) 1 (0.5) N.A.
STEMI (%) 5 (1.3) 2 (1.1) 3 (1.6) 0.64
NSTEMI (%) 8 (2.1) 6 (3.1) 2 (1.1) 0.16
Target vessel revascularization (%) 7 (1.9) 2 (1.1) 5 (2.7) 0.25
Non-target lesion revascularization (%) 66 (17.4) 40 (20.9) 26 (13.8) 0.07
CABG (%) 15 (4.0) 10 (5.2) 5 (2.7) 0.20
Hospitalization for heart failure (%) 3 (0.8) 3 (1.6) – N.A.
Hospitalization for chest pain (%) 43 (11.4) 23 (12.0) 20 (10.6) 0.60
ICD implantation (%) 13 (3.4) 8 (4.2) 5 (2.7) 0.41
Stroke (%) 3 (0.8) 1 (0.5) 2 (1.1) N.A.
New-onset diabetes mellitus (%) 66 (17.4) 34 (17.8) 32 (17.0) 0.84
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not significantly different between metformin and placebo 
treated patients (Table 1). Three (1.6%) patients in the met-
formin group died compared to 1 (0.5%) in the placebo 
group. New-onset DM was 34 (17.8%) in metformin and 32 
(17.0%) in placebo treated patients (OR 1.15, CI 0.66–1.98, 
P = 0.84). Potential confounding by differences in concom-
itant medication use during 2-year follow-up was evaluated 
and no differences were observed (Table 2). NT pro-BNP 
levels over time were not significantly different between 
treatment groups (P = 1.00) (Fig. 2).
Discussion
The GIPS-III trial is the first prospective study evaluating 
the effect of 4  months of metformin treatment in patients 
without DM, presenting with STEMI. The primary end-
point of the GIPS-III trial, LVEF at 4  months, was not 
affected by metformin treatment [6]. In the present study 
we now provide 2-year follow-up data and evaluated 
predefined secondary endpoints including MACE. We 
observed a similar incidence of MACE between patients 
who received metformin or placebo treatment for 4 months 
after STEMI. Other predefined secondary endpoints includ-
ing all-cause mortality and new-onset DM did not differ 
between the treatment groups.
Previous data on the effects of metformin in MI origi-
nate predominantly from animal experimental or human 
observational data and are inconsistent. For example, some 
studies have reported a decrease in myocardial infarct size 
due to metformin [4] while others suggested no effect 
[10]. It has also been suggested that in patients with DM 
presenting with MI, chronic metformin use might reduce 
30-day all-cause mortality, although 12-month all-cause 
mortality was not significantly different [11]. Metformin 
also did not affect LVEF in these patients at 12 months 
[11]. The prospective Metformin in Coronary Artery 
Bypass Graft (MetCAB) trial investigated pretreatment of 
metformin in 100 patients undergoing CABG, and did not 
observe a reduction in periprocedural myocardial injury 
based on assessment of Troponin I levels [12]. Though, 
periprocedural myocardial injury is mostly limited and not 
comparable to the extent of myocardial injury caused by 
MI. Besides, a different underlying pathophysiologic pro-
cess might play a role, which could be an explanation why 
metformin was not effective.
In the current analyses of GIPS-III we did not observe 
a beneficial effect of 4  months of metformin treatment 
on long-term clinical outcomes, even when taking into 
account potential confounding by concomitant medical 
therapy. The incidence of MACE during 2-year follow-
up was low and the same applies for heart failure hospi-
talizations and ICD implantations. This is probably due 
to the efficient local STEMI protocol resulting in short 
ischemia times and successful reperfusion in the majority 
of patients. In addition, all STEMI patients received med-
ical therapy as recommended by current guidelines [1]. 
Patients of the GIPS-III trial had relatively small infarct 
size and largely preserved LVEF as measured by CMR at 
4 months [6], both of which are associated with favora-
ble outcomes [13, 14]. However, it should be mentioned 
that 28% of the study population did not undergo CMR 
and selection bias may have distorted these findings. One 
study showed that CMR dropouts in general had a worse 
Fig. 1  Kaplan–Meier curve 
representing MACE-free sur-
vival during 2-year follow-up 
in the metformin and placebo 
treatment groups. MACE-free 
survival was not significantly 
different between the groups 
(Log-rank test P = 0.22)
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Table 2  Medication use during 
2-year follow-up
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker
Medication Total (N = 379) Metformin (N = 191) Placebo (N = 188) P value
Medication use at discharge (%) 379 (100)
 Aspirin (%) 367 (96.8) 184 (96.3) 183 (97.3) 0.77
 Thienopyridine (%) 379 (100) 191 (100) 188 (100) 1.00
 Coumarin (%) 20 (5.3) 13 (6.8) 7 (3.7) 0.25
 Beta blocker (%) 362 (95.5) 179 (93.7) 183 (97.3) 0.14
 ACE inhibitor or ARB (%) 301 (79.4) 158 (82.7) 143 (76.1) 0.13
 Statin (%) 377 (99.5) 190 (99.5) 187 (99.5) 1.00
 Antidiabetic drugs (%) 7 (1.9) 4 (2.1) 3 (1.6) 1.00
Medication use at 3-4 months (%) 356 (93.9)
 Aspirin (%) 346 (97.2) 171 (96.1) 175 (98.3) 0.34
 Thienopyridine (%) 349 (98.0) 174 (97.8) 175 (98.3) 1.00
 Coumarin (%) 26 (7.3) 17 (9.6) 9 (5.1) 0.15
 Beta blocker (%) 340 (95.5) 170 (95.5) 170 (95.5) 1.00
 ACE inhibitor or ARB (%) 276 (77.5) 133 (74.7) 143 (80.3) 0.25
 Statin (%) 343 (96.4) 173 (97.2) 170 (95.5) 0.57
 Antidiabetic drugs (%) 7 (2.0) 5 (2.8) 2 (1.1) 0.45
Medication use at 2 years (%) 370 (97.6)
 Aspirin (%) 356 (96.2) 178 (95.7) 178 (96.7) 0.79
 Thienopyridine (%) 24 (6.5) 9 (4.8) 15 (8.2) 0.21
 Coumarin (%) 25 (6.8) 15 (8.1) 10 (5.4) 0.41
 Beta blocker (%) 316 (85.4) 160 (86.0) 156 (84.8) 0.77
 ACE inhibitor or ARB (%) 249 (67.3) 120 (64.5) 129 (70.1) 0.27
 Statin (%) 332 (89.7) 172 (92.5) 160 (87.0) 0.09
 Antidiabetic drugs (%) 23 (6.2) 11 (5.9) 12 (6.5) 0.83
Fig. 2  Median NT pro-BNP 
levels during 2-year follow-up 
in the metformin treatment and 
placebo treatment group. Levels 
were not significantly differ-
ent between the groups (linear 
mixed effects P = 0.35)
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baseline clinical risk profile, although this had no effect 
on clinical endpoints [15]. Apart from the expected non-
target vessel revascularizations diagnosed during the ini-
tial STEMI event, the incidence of revascularizations in 
the GIPS-III trial was remarkably low. As suggested in 
the review of Lexis et  al. [16], metformin could play a 
role in the prevention of restenoses, although this was 
not confirmed in our study. Limitations of this work that 
warrant consideration are the fact that the GIPS-III trial 
was primarily designed to detect the effect of metformin 
on LVEF with 80% power. Besides, other long-term fol-
low-up studies with smaller patient populations found 
MACE incidences ranging from 25 to 35% as compared 
to 4.5% in the GIPS-III cohort [17–19]. The unexpected 
low incidence of MACE, which might have ensued from 
the efficient local STEMI protocol resulting in relatively 
small infarct size, has led to insufficient power to rule 
out beneficial effects of metformin on predefined clinical 
endpoints with certainty. The overall low rate of new car-
diovascular events implies that with the current treatment 
strategy of reperfusion therapy and secondary prevention 
we are able to accomplish a favorable outcome in most 
patients. Hence, we might have reached a phase in clini-
cal care to which additional therapies might be of only 
limited additional value when STEMI patients receive 
optimal reperfusion therapy.
Several considerations have been discussed previously 
in defense of the moderate dose of metformin used in the 
GIPS-III trial [6]. In an open-label randomized controlled 
clinical trial including patients with metabolic syndrome 
undergoing elective PCI, treatment with a total dose of 
750  mg metformin prior to the procedure resulted in less 
cardiac biomarker release and a favorable outcome at 
1-year follow-up [20]. As the lower dose used in this study 
with a similar population already showed to be effective, a 
higher dose up to 3000 mg is not expected to give a differ-
ent outcome in our study.
The timing and duration of metformin treatment might 
play a crucial role in its potential cardioprotective effects. 
The majority of the previous experimental and obser-
vational data reported protective effects in the setting of 
metformin administration before or during reperfusion 
[4]. In the GIPS-III trial, metformin was administered 
directly after PCI and effective plasma levels were prob-
ably achieved hours later, resulting in a shorter window 
of opportunity to modify ischemia–reperfusion injury. In 
animal models, ischemic reperfusion injury has been sug-
gested to contribute up to 50% to the final size of MI [21]. 
We cannot exclude that metformin therapy initiated prior 
to PCI might indeed reduce myocardial infarct size as has 
been suggested by prior data [4, 22, 23]. Several mecha-
nisms have been postulated to play a key role in explaining 
the effect of early treatment [24–27]. Nonetheless, we did 
not observe a positive effect with the applied strategy of 
post-PCI metformin administration on infarct size nor on 
other endpoints.
Furthermore, sex-dependent differences in the metabolic 
and functional response to metformin have been suggested 
[10]. Metformin therapy decreases fatty acid clearance 
which consequently results in increased fatty acid plasma 
levels and myocardial fatty acid utilization and oxidation in 
men, which has been linked to adverse clinical outcomes 
in myocardial ischemia setting [28]. The opposite has been 
observed in women. In the GIPS-III trial the majority of 
patients were males, which limits us to detect a potential 
positive effect of metformin treatment in females.
Previous studies demonstrated that metformin therapy 
can prevent or delay the onset of type II DM [29, 30]. We 
did not observe an effect of 4 months metformin treatment 
on the incidence of DM after 4-month follow-up [7], or in 
this analysis after 2-year follow-up. The treatment duration 
of 4 months in the GIPS-III trial, as opposed to 1.5–3 years 
in other studies, might not be long enough [30, 31], and 
the pharmacological effects of metformin might not per-
sist after discontinuation. With 17% of patients developing 
DM our study does confirm that patients, after their first 
STEMI, should be followed for new-onset DM. Starting 
with lifestyle interventions, especially in case of impaired 
glucose tolerance, is recommended in STEMI patients [1].
Currently, several clinical trials, in ischemic as well 
as non-ischemic settings, are evaluating the effect of 
metformin on diverse cardiovascular endpoints (Online 
Resource 1). These trials will provide further insight into 
the potential clinical value of metformin treatment in car-
diovascular disease.
To conclude, in this 2-year follow-up of the GIPS-
III trial we observed no differences between STEMI 
patients treated with metformin versus placebo on prede-
fined secondary endpoints, including MACE. Moreover, 
no effect was seen on the incidence of new-onset DM in 
both groups. On the one hand, the overall low incidence 
of MACE prohibited us to definitely rule out long-term 
beneficial effects of metformin in STEMI patients without 
DM. On the other hand, the low rate of new cardiovascu-
lar events in a population with optimal reperfusion ther-
apy and secondary prevention might imply that we have 
reached a phase in clinical care to which additional thera-
pies are of only limited additional value. This might also 
be a consideration in the design of future interventional 
studies in STEMI patients.
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